Review shows federal regulators accepted reduced drinking as a primary endpoint in medication trials, suggesting expanded access to AUD treatments.
Findings from a newly published review of alcohol research suggest that federal regulators' decision last January to accept a measure of reduced drinking as a primary endpoint in medication trials could expand access to beneficial treatments for alcohol use disorder (AUD).
No takes yet. Share an insight, caveat, or question.
Gary Enos (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: